Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935870 | 0.91 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL5741535 | 0.91 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3938757 | 0.89 | CDK1 (1.00) | CDK1CDK2KDR | |
| SCHEMBL3934020 | 0.88 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3937430 | 0.88 | CDK1 (1.00) | CDK1CDK2KDR | |
| SCHEMBL13944388 | 0.88 | CDK2 (0.78) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3939340 | 0.87 | CDK1 (0.85) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3929323 | 0.84 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3581267 | 0.84 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL2818622 | 0.83 | CDK1 (0.70) | CDK1CDK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507510-B2 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507510-B2 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| EP-1673352-B1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CD AND/OR VEGF-INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | BAYER SCHERING PHARMA AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| EP-1673352-B1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CD AND/OR VEGF-INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | BAYER SCHERING PHARMA AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | CDK2, CDK1, FLT1 | CDK1 2/4885CDK2 1/4885KDR 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.